BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

Advent Life Sciences’ latest funds include a tie-up with the Harrington Discovery Institute, providing the trans-Atlantic VC with an early look at innovation coming out of the Cleveland-area accelerator. On Thursday, Advent announced the close of...
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday after the companies priced IPOs on NASDAQ Thursday night. Hearing and balance therapy company Decibel raised $127.1 million through the sale of 7.1 million shares...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai in 1987, has served as president of Roche Products (Ireland) Ltd.,...
BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

Strong performance and continued broad interest in life sciences led to Abingworth raising its largest-ever fund, with the trans-Atlantic VC putting more energy into company creation and co-development...
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and Canada, with Coherus gaining exclusive commercialization rights in both countries. Junshi...
Items per page:
1 - 10 of 1260
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

Advent Life Sciences’ latest funds include a tie-up with the Harrington Discovery Institute, providing the trans-Atlantic VC with an early look at innovation coming out of the Cleveland-area accelerator. On Thursday, Advent announced the close of...
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday after the companies priced IPOs on NASDAQ Thursday night. Hearing and balance therapy company Decibel raised $127.1 million through the sale of 7.1 million shares...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai in 1987, has served as president of Roche Products (Ireland) Ltd.,...
BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

Strong performance and continued broad interest in life sciences led to Abingworth raising its largest-ever fund, with the trans-Atlantic VC putting more energy into company creation and co-development...
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and Canada, with Coherus gaining exclusive commercialization rights in both countries. Junshi...
Items per page:
1 - 10 of 1260